Janet E. Rush

1.3k total citations
23 papers, 866 citations indexed

About

Janet E. Rush is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Janet E. Rush has authored 23 papers receiving a total of 866 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cardiology and Cardiovascular Medicine, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Janet E. Rush's work include Heart Failure Treatment and Management (8 papers), Venous Thromboembolism Diagnosis and Management (4 papers) and Renal Transplantation Outcomes and Treatments (3 papers). Janet E. Rush is often cited by papers focused on Heart Failure Treatment and Management (8 papers), Venous Thromboembolism Diagnosis and Management (4 papers) and Renal Transplantation Outcomes and Treatments (3 papers). Janet E. Rush collaborates with scholars based in United States, United Kingdom and Switzerland. Janet E. Rush's co-authors include Elliott M. Antman, Carolyn H. McCabe, Eugene Braunwald, Marc Cohen, David Radley, Jerôme Premmereur, Debora Merrill, Natalie J. Warner, Richard C. Becker and Sabina A. Murphy and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

Janet E. Rush

23 papers receiving 807 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janet E. Rush United States 12 632 306 224 124 110 23 866
Michael B. Jorgensen United States 12 1.0k 1.6× 197 0.6× 520 2.3× 99 0.8× 189 1.7× 17 1.4k
Mark Robbins United States 14 709 1.1× 69 0.2× 460 2.1× 87 0.7× 132 1.2× 25 1.0k
Sergio Dalla‐Volta Italy 12 622 1.0× 236 0.8× 136 0.6× 140 1.1× 91 0.8× 34 769
Periaswamy Velavan United Kingdom 12 518 0.8× 175 0.6× 219 1.0× 59 0.5× 77 0.7× 23 623
Marie‐Odile Benoit France 10 272 0.4× 167 0.5× 122 0.5× 49 0.4× 55 0.5× 13 531
A. Pitt Australia 13 488 0.8× 94 0.3× 188 0.8× 110 0.9× 109 1.0× 34 711
Martin Gardien Netherlands 7 347 0.5× 79 0.3× 286 1.3× 67 0.5× 123 1.1× 13 811
A.A.J. Adgey United Kingdom 20 857 1.4× 76 0.2× 255 1.1× 194 1.6× 64 0.6× 62 1.1k
Sergio Cannizzaro Italy 13 411 0.7× 117 0.4× 70 0.3× 48 0.4× 64 0.6× 31 519
Janina Stępińska Poland 18 719 1.1× 58 0.2× 260 1.2× 132 1.1× 112 1.0× 111 1.0k

Countries citing papers authored by Janet E. Rush

Since Specialization
Citations

This map shows the geographic impact of Janet E. Rush's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet E. Rush with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet E. Rush more than expected).

Fields of papers citing papers by Janet E. Rush

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet E. Rush. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet E. Rush. The network helps show where Janet E. Rush may publish in the future.

Co-authorship network of co-authors of Janet E. Rush

This figure shows the co-authorship network connecting the top 25 collaborators of Janet E. Rush. A scholar is included among the top collaborators of Janet E. Rush based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet E. Rush. Janet E. Rush is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nashan, Björn, Martijn W.F. van den Hoogen, Diane M. Cibrik, et al.. (2018). CD40 Inhibition with CFZ533 - A New, Fully Human, Non-Depleting, Fc Silent mAB - Improves Renal Allograft Function While Demonstrating Comparable Efficacy vs. Tacrolimus in De-Novo CNI-Free Kidney Transplant Recipients. Transplantation. 102(Supplement 7). S366–S366. 8 indexed citations
2.
Rush, Janet E., Mark D. Kittleson, Frank Liou, et al.. (2015). Is There a Risk of Cocaine and Methamphetamine Use in Heart Donors?. The Journal of Heart and Lung Transplantation. 34(4). S276–S277. 3 indexed citations
3.
Widemann, Brigitte C., Stefan Schwartz, Nalini Jayaprakash, et al.. (2013). Efficacy of Glucarpidase (Carboxypeptidase G 2) in Patients with Acute Kidney Injury After High‐Dose Methotrexate Therapy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 34(5). 427–439. 61 indexed citations
4.
Rush, Janet E., M. Kittleson, A. Velleca, et al.. (2013). Men Versus Women: Outcome Differences on Cyclosporine and Tacrolimus. The Journal of Heart and Lung Transplantation. 32(4). S201–S201. 2 indexed citations
5.
6.
Wright, David, et al.. (2009). High prevalence of right-to-left shunt in patients with symptomatic great saphenous incompetence and varicose veins. Journal of Vascular Surgery. 51(1). 104–107. 14 indexed citations
7.
Becker, Richard C., Frederick A. Spencer, Michael Gibson, et al.. (2002). Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. American Heart Journal. 143(5). 753–759. 130 indexed citations
8.
Taylor, T. G., et al.. (2000). CEREBRAL INFARCTION AND MYOCARDIAL FIBROSIS IN A WHITE-HANDED GIBBON (HYLOBATES LAR). Journal of Zoo and Wildlife Medicine. 31(1). 65–70. 8 indexed citations
9.
Freeman, Lisa M., Donald D. Brown, F. W. Smith, & Janet E. Rush. (1997). Magnesium status and the effect of magnesium supplementation in feline hypertrophic cardiomyopathy.. PubMed. 61(3). 227–31. 6 indexed citations
10.
Rush, Janet E., et al.. (1995). Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the invasive multicenter PROspective veterinary evaluation of enalapril study. 32 indexed citations
11.
Rush, Janet E. & Sol I. Rajfer. (1993). Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure.. PubMed. 11(3). S69–71. 11 indexed citations
12.
Maher, E.R. & Janet E. Rush. (1990). Cardiovascular changes in the geriatric dog.. Compendium on Continuing Education for The Practicing Veterinarian. 12(7). 921–931. 5 indexed citations
13.
Giles, Thomas D., Richard J. Katz, Jay M. Sullivan, et al.. (1989). Short- and long-acting angiotensin-converting enzyme inhibitors: A randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. Journal of the American College of Cardiology. 13(6). 1240–1247. 95 indexed citations
14.
Stone, Charles K., Barry F. Uretsky, Thomas J. Linnemeier, et al.. (1989). Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. The American Journal of Cardiology. 63(9). 567–570. 7 indexed citations
15.
Warner, Natalie J., et al.. (1989). Tolerability of enalapril in congestive heart failure. The American Journal of Cardiology. 63(8). D33–D37. 15 indexed citations
16.
Giles, Thomas D., et al.. (1988). Lisinopril and captopril in the treatment of heart failure in older patients. The American Journal of Medicine. 85(3). 44–47. 13 indexed citations
17.
Rush, Janet E. & Paulette A. Lyle. (1988). Safety and tolerability of lisinopril in older hypertensive patients. The American Journal of Medicine. 85(3). 55–59. 6 indexed citations
18.
19.
Warner, Natalie J. & Janet E. Rush. (1988). Safety Profiles of the Angiotensin-Converting Enzyme Inhibitors. Drugs. 35(Supplement 5). 89–97. 25 indexed citations
20.
Rush, Janet E. & Debora Merrill. (1987). The Safety and Tolerability of Lisinopril in Clinical Trials. Journal of Cardiovascular Pharmacology. 9. S99–S107. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael B. Jorgensen Breakdown of academic impact, for papers by Mark Robbins Breakdown of academic impact, for papers by Sergio Dalla‐Volta Breakdown of academic impact, for papers by Periaswamy Velavan Breakdown of academic impact, for papers by Marie‐Odile Benoit Breakdown of academic impact, for papers by A. Pitt Breakdown of academic impact, for papers by Martin Gardien Breakdown of academic impact, for papers by A.A.J. Adgey Breakdown of academic impact, for papers by Sergio Cannizzaro Breakdown of academic impact, for papers by Janina Stępińska
Rankless by CCL
2026